Literature DB >> 11449487

Premature ovarian failure in the fragile X syndrome.

S L Sherman1.   

Abstract

The full mutation leading to the fragile X syndrome is a dynamic trinucleotide repeat located in the 5' untranslated region of the FMR1 gene. The premutation allele contains approximately 60 to 199 repeats, is unstable, and originally not considered detrimental; that is, there did not appear to be a phenotype consequence of the long repeat tract. However, in the late 1980s and early 1990s, preliminary findings suggested that nonimpaired heterozygotes were at risk of early menopause and increased rates of twinning, both indications of ovarian failure. Once premutation carriers could be distinguished from full mutation carriers, this phenotype was found to be restricted to premutation carriers only. Based on the recent studies reviewed here, approximately 21% of premutation carriers have premature ovarian failure (POF) compared to only 1% in the general population, or a relative risk of 21. Moreover, among women with idiopathic sporadic or the more rare form of familial POF, approximately 2% and 14%, respectively, carry the premutation. To date, data supporting increased twinning rates are conflicting and need to be resolved. Neither the underlying cellular pathophysiology of POF caused by the premutation allele nor molecular mechanism underlying the presence of the long repeat tract of the premutation allele is understood. Irrespective, women who carry the premutation allele should have not only genetic counseling but also fertility counseling to ensure that they reach their goals for reproduction.

Entities:  

Mesh:

Year:  2000        PMID: 11449487     DOI: 10.1002/1096-8628(200023)97:3<189::AID-AJMG1036>3.0.CO;2-J

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  150 in total

1.  The fragile X syndrome repeats form RNA hairpins that do not activate the interferon-inducible protein kinase, PKR, but are cut by Dicer.

Authors:  Vaishali Handa; Tapas Saha; Karen Usdin
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 2.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

Review 3.  Ovarian aging and premature ovarian failure.

Authors:  Yavuz Emre Sükür; Içten Balık Kıvançlı; Batuhan Ozmen
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-08-08

Review 4.  The impact of FMR1 gene mutations on human reproduction and development: a systematic review.

Authors:  Vincenzo Noto; Conor Harrity; David Walsh; Kevin Marron
Journal:  J Assist Reprod Genet       Date:  2016-07-18       Impact factor: 3.412

5.  Living with genetic risk: effect on adolescent self-concept.

Authors:  Allyn McConkie-Rosell; Gail A Spiridigliozzi; Elizabeth Melvin; Deborah V Dawson; Ave M Lachiewicz
Journal:  Am J Med Genet C Semin Med Genet       Date:  2008-02-15       Impact factor: 3.908

Review 6.  Recent advances in assays for the fragile X-related disorders.

Authors:  Bruce E Hayward; Daman Kumari; Karen Usdin
Journal:  Hum Genet       Date:  2017-09-02       Impact factor: 4.132

7.  FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.

Authors:  Karla L Bretherick; Margo R Fluker; Wendy P Robinson
Journal:  Hum Genet       Date:  2005-06-02       Impact factor: 4.132

8.  Fragile X screening: attitudes of genetic health professionals.

Authors:  Kruti Acharya; Lainie Friedman Ross
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

9.  Levels and associations among self-esteem, fertility distress, coping, and reaction to potentially being a genetic carrier in women with diminished ovarian reserve.

Authors:  Ceylan Cizmeli; Marci Lobel; Jason Franasiak; Lisa M Pastore
Journal:  Fertil Steril       Date:  2013-03-15       Impact factor: 7.329

10.  Co-occurring diagnoses among FMR1 premutation allele carriers.

Authors:  J E Hunter; J K Rohr; S L Sherman
Journal:  Clin Genet       Date:  2010-01-06       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.